Establishment of novel therapeutic strategy against neuroendocrine lung cancer through regulation of malignant neural phenotype

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08360
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Human pathology
• Research Institution: Dokkyo Medical University (2016-2017); Chiba University (2015)
• Principal Investigator: YAZAWA TAKUYA 獨協医科大学, 医学部, 教授 (50251054)
• Co-Investigator(Kenkyū-buntansha): 原 由紀子 東京医科大学, 医学部, 准教授 (40313267) ; 矢澤 華子 (佐藤) 獨協医科大学, 医学部, 講師 (60438132) ; 三好 洋 聖マリアンナ医科大学, 医学部, 助手 (80322519)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 肺癌 / 神経内分泌肺癌 / 非神経内分泌肺癌 / 形質転換 / 遺伝子治療

Outline of Final Research Achievements

We had experienced that POU3F4 or POU4F2 transgene made non-neuroendocrine lung cancer (NNELC) cells cause transformation to neuroendocrine lung cancer (NELC). Carrying out this study, it was clarified that the transformation from NNELC to NELC is a direct reprogramming phenomenon and that breakdown of a neural cell-specific NOTCH-HES pathway, which is activated by POU3F4/4F2 transgene, diminish neuroendocrine phenotype.

Free Research Field

人体病理学